Opinion|Videos|October 18, 2024
Lupus Nephritis Management: Monitoring Strategies and Long-Term Study Results
Key Takeaways
- Regular assessment of renal function, proteinuria, and serological markers is crucial for monitoring lupus nephritis progression and treatment response.
- Long-term follow-up data offer valuable insights into the sustained efficacy and safety of lupus nephritis treatments.
Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost-effectiveness in LN management.
Advertisement
Episodes in this series
- How do you monitor patients with lupus nephritis for disease progression and treatment response? (Dr. Larranaga)
- Three-year follow-up results of voclosporin from the AURORA-2 study were
published earlier this year. What is the value of long-term follow-up data such as these in lupus nephritis? (Dr. Wells)
Advertisement
Related to this article
Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.
A real-world trial found 42.6% of patients with severe hand eczema cleared on oral alitretinoin.
AMCP Nexus 2026 brings managed care leaders to San Diego October 26-29 to tackle Medicare negotiation, drug pricing policy, AI, and patient access.
IDWeek 2026 posters describe a rule-based tool classifying about 1 in 5 patients with cUTI as outpatient-eligible and 5 clusters with varied LOS.
Insmed’s once-daily TPIP prodrug shows sustained lung vasodilation in PAH and PH-ILD, improving walk distance and other key measures.
An international eDelphi panel of 62 dermatologists agreed on a 2-step algorithm for tapering psoriasis biologics.
Advertisement
Advertisement
Trending on AJMC
1
Awareness Gaps Drive Narcolepsy, IH Delays: Logan Schneider, MD
2
Extension Studies in TPIP Show Promise in PAH, PH-ILD
3
Administrative Burden Keeps Clinicians From Bedside: Amy Morris, MD
4
International Panel Agrees on Framework for Tapering Psoriasis Biologics
5